Pfizer stops listing Covid-19 drug Paxlovid in standard risk groups
(RTTNews) – Vaccine maker Pfizer Inc. (PFE) said it was ending enrollment in a trial for its Covid-19 antiviral drug, Paxlovid, in standard-risk patients. The decision was made after a study found the treatment was not effective in reducing symptoms in this group. The drug has been granted emergency use authorization for people in high-risk groups where it has been shown to be effective in reducing rates of hospitalizations and deaths. The latest data, however, showed a relative risk reduction of 51% in the standard risk groups, which the vaccine maker said was not statistically significant. The standard-risk population includes people who do not have medical conditions that put them at risk for serious disease and who can recover without the drug. Pfizer said the new data would be included in its next submission to the US FDA seeking full approval for the drug’s use in high-risk groups.
Data from a study conducted in Israel in early June found that COVID-19 lowers hospitalization and death rates in vaccinated and unvaccinated patients aged 65 and older, but did not. stopped serious illnesses in young adults. More than 1.2 million courses of Paxlovid have been administered in the United States, according to data from the Assistant Secretary for Preparedness and Response for the US Department of Health and Human Services.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.